Patterns of Immunohistochemical Expression of P53, BCL2, PTEN, and HER2/neu Tumor Markers in Specific Breast Cancer Lesions

Mohamed Ahmed Bealy; Awad Aljeed Abugooda; Ruba Mustafa Elsaid Ahmed; Nuha Abdel Rahman Khalil; Abdelbaset Mohamed Elasbali; Ghorashy Eltayeb Yousif Mohamed; Faris Merghani Eltom; Hussain Ahmed

doi:10.1155/2022/2026284

Patterns of Immunohistochemical Expression of P53, BCL2, PTEN, and HER2/neu Tumor Markers in Specific Breast Cancer Lesions

Evid Based Complement Alternat Med. 2022 Oct 17:2022:2026284. doi: 10.1155/2022/2026284. eCollection 2022.

Authors

Mohamed Ahmed Bealy^{1

2}, Awad Aljeed Abugooda³, Ruba Mustafa Elsaid Ahmed¹, Nuha Abdel Rahman Khalil¹, Abdelbaset Mohamed Elasbali⁴, Ghorashy Eltayeb Yousif Mohamed¹, Faris Merghani Eltom⁵, Hussain Ahmed³

Affiliations

¹ Department Pathology, College of Medici University of Ha'il-Saudi Arabia, Ha'il, Saudi Arabia.
² Department Histopathology and Cytology Faculty of Medical Laboratory Sciences (FMLS) University of Kordofan-Elobeid-Sudan, Elobeid, Sudan.
³ Department of Histopathology and Cytology FMLS University of Khartoum-Sudan, Khartoum, Sudan.
⁴ Clinical Laboratory Science, College of Applied Medical Science- Qurayyat, Jouf University, Qurayyat, Saudi Arabia.
⁵ Department of Histology, College of Medicine, Alrayan Colleges, Almadinah Almunawwarah, Saudi Arabia.

Abstract

Objective: This study aimed to associate the expression of P53, BCL2, PTEN, and HER2/neu tumor markers in specific breast cancer lesions.

Methods: This study analyzed the immunohistochemical expression of P53, BCL2, PTEN, and HER2/neu tumor markers for 306 patients who presented with lesions. Tissue blocks and patients' identification data were retrieved from the department of pathology, AL Madinah Almonwarah hospital, Al Madinah, UAE.

Results: Of the 306 patients, 104 had benign lesions and 202 had malignancy (including 194 females and 6 males). Most females were presented with invasive ductal carcinoma (IDC), followed by infiltrating ductal carcinoma, and invasive lobular carcinoma (ILC), representing 70%, 23.2%, and 3.7%, respectively. Positive P53, BCL2, PTEN, and HER2 were identified in 20.8%, 11.9%, 91%, and 18.3%, respectively.

Conclusion: : The expression of P53, BCL2, PTEN, and HER2/neu tumor markers among Saudi patients with breast cancer is relatively similar in many parts of the world.